Fig. 2: In vivo tumor growth assay.
From: β2-AR inhibition enhances EGFR antibody efficacy hampering the oxidative stress response machinery
a Schematic in vivo experimental design. b Ex vivo tongue collection and tumor fluorescence documentation. c Tumor growth rate of mice treated with CTX and U0126 alone or in combination with ICI. A significant delay is reported in ICI + CTX-treated tumor-bearing mice (**P ≤ 0.01 vs. CTR).
